Business Wire

MICROSURE

7.6.2019 12:39:10 CEST | Business Wire | Press release

Share
Microsure’s MUSA Microsurgery Robot Receives CE-mark

MUSA is the world’s first surgical robot for open microsurgery. This robotic assistant is clinically and commercially available after the medical device CE-mark was issued by notified body DEKRA recently. Microsure’s MUSA is developed by a team of microsurgeons and engineers, creating a high-precision robotic assistant that is compatible with current operating techniques, workflow, instruments and other OR-equipment. It enhances surgical performance by stabilizing and scaling down the surgeon’s movements during complex microsurgical procedures on sub-millimeter scale.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190607005175/en/

Microsure’s MUSA e.g. enables lymphatic surgery on lymph vessels smaller than 0.3 mm in diameter. Plastic surgeons at Maastricht University Medical Center+ were the first to use MUSA to surgically treat lymphedema in a patient. This world's premier super-microsurgical intervention with 'robot hands' took place in 2017. Maastricht University Medical Center+ is now conducting several follow up clinical research projects with MUSA, in different fields of microsurgery. Other European hospitals are expected to start clinical studies this year.

Microsurgery procedures with MUSA

Surgical procedures that maximally benefit from Microsure’s MUSA are complex surgeries on small tissue structures –for instance LVA (Lymphovenous Anastomosis) surgery, pediatric vascalar surgery, free flap surgery, finger and hand replantation – when human precision is the limiting factor because of physiological tremor, poor accessibility or fatigue. Various studies and pilots have proven safe and effective clinical use of the device.

ISO 13485 certification

Microsure also received the ISO 13485 certificate, another major milestone. The ISO certification assures that Microsure is adhering to the highest standards in quality management and regulatory compliance procedures to develop, manufacture, and test its products and services. ISO 13485:2016 is the latest update to ISO requirements for a comprehensive quality management system for the design and manufacture of medical devices.

Microsure

Microsure is a medical device company in Eindhoven (The Netherlands) founded by Eindhoven University of Technology and Maastricht University Medical Center in 2016, funded by Innovation Industries Fund. Microsure’s focus is to improve patients’ quality of life through developing robot systems for microsurgery. Its current product is MUSA, the world’s first surgical robot for open microsurgery. MUSA has been designed by microsurgeons and engineers, specifically for microsurgical applications. MUSA provides superhuman precision for microsurgeons, enabling new interventions that are currently impossible to perform by hand. www.microsure.nl

Contact:

Microsure Lars Schiemanck (CEO) l.schiemanck@microsure.nl +31 686 692 887

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology16.6.2026 19:00:00 CEST | Press release

Court orders Siemens to halt production and recall and destroy products across Germany, France and the Netherlands Hologic, Inc. today announced a significant and far-reaching victory in the Unified Patent Court (UPC) in Germany, which ruled that Siemens* infringed upon a critical Hologic mammography technology patent in Siemens’ latest mammography system. The court imposed a sweeping injunction, immediately prohibiting Siemens from making, offering, placing on the market, using or importing or storing for those purposes its MAMMOMAT B.brilliant systems across Germany, France and the Netherlands, as well as monetary damages and penalties for non-compliance. The court also required Siemens to execute a mandatory recall and destruction of all affected systems in those countries. On June 10, 2026, the UPC determined that Siemens infringed upon European Patent EP 2 352 431, Hologic’s Focusing Technology on the Envision™ Platform, the first FDA-approved mammography innovation of its kind.1

RealTime Reservation Acquires STAY to Create Leading Global Guest Experience Platform Serving 2,000+ Properties Across 75+ Countries16.6.2026 18:30:00 CEST | Press release

Wavecrest Growth Partners invests to enable combination and support growth of the combined company RealTime Reservation (RTR), the industry leader in dynamic hospitality booking technology for onsite activities, amenities, and ancillary revenue management, today announced its acquisition of STAY, creating a global end-to-end guest experience platform for the hospitality industry. The combined company will serve more than 2,000 hospitality properties across 75+ countries throughout North America, Europe, Latin America and the Caribbean. The combination significantly expands RTR's international footprint and strengthens its position as a leading provider of guest engagement, ancillary revenue, and guest experience technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616258776/en/ Pictured: RealTime Reservation's dynamic booking interface allows hotel guests to select and reserve pool and beach amenities by location, d

Happy Holidays S.A. and JTA Investment Holding Announce €65 Million Investment for SARTIMARE Tourism Development in Greece16.6.2026 17:42:00 CEST | Press release

Happy Holidays S.A. today announced the signing of an Investment Agreement with Qatar-based JTA Investment Holding for the development of the sustainable SARTIMARE Beach Resort & Spa project in Sarti, Halkidiki, Greece. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616892834/en/ Dr. Amir Ali Salemi Zadeh, CEO of JTA Investment Holding and Georgios Iosifidis, Founder & Owner of Happy Holidays S.A. Under the agreement, JTA Investment Holding will invest €65 million into the development. The project will be built on a site of approximately 120,900 square meters, with construction scheduled between 2027 and 2030. Designed with a strong commitment to environmental responsibility, the SARTIMARE project will feature luxury hospitality facilities, premium residences and villas, wellness amenities, retail, food & beverage outlets, and marina infrastructure. The project's valuation is expected to exceed €100 million as key develop

IFF and ISIPCA Mark 10 Years of Joint Scent Design and Creation Master’s-Level Program16.6.2026 17:00:00 CEST | Press release

A pioneering perfumery program that develops industry-ready talent IFF — a global leader in flavors, fragrances, food ingredients and health & biosciences — celebrates the 10th anniversary of its industry-leading accredited master's-level program for scent design and creation, developed in partnership with ISIPCA, the world-renowned school for careers in perfume, cosmetics and food flavors. Since its launch in 2016, the IFF ISIPCA program has trained more than 180 professionals from 40 countries, with 130 graduates to date, and a 100% job landing rate up to six months after graduation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615461626/en/ The IFF ISIPCA Scent Design and Creation program has been pioneering fragrance education and excellence since 2016. “Over the past decade, IFF ISIPCA has built a strong pipeline of diverse, high-potential fragrance experts, combining creative excellence, scientific expertise and a

Fenchurch Advisory Partners to Combine With Broadhaven Capital Partners, Creating the Preeminent International Investment Bank Serving the Financial Services Sector16.6.2026 16:30:00 CEST | Press release

Fenchurch Advisory Partners has entered into a definitive agreement to combine with Broadhaven Capital Partners, a leading independent advisory firm to the financial technology and financial services sectors in North America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616214669/en/ Fenchurch is one of the most respected investment banking advisory firms dedicated exclusively to the financial services sector. With offices in London, New York and Paris, Fenchurch provides trusted, independent advice to corporates and financial sponsors across insurance, asset and wealth management, banking, and specialty finance. In 2025, Fenchurch advised on 27 transactions, ranking as the number one adviser to the financial services sector in the UK and Europe. Founded in 2009, Broadhaven has established itself as a premier investment bank advising corporates and financial sponsors on M&A, capital raising, and strategic transactions,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye